Who
David Lee Johnson
Chief Operating Officer
Company insider
Files Form 4 as: Chief Operating Officer, Vera Therapeutics; Director, Caribou Biosciences; Chief Commercial Officer, Global Blood Therapeutics.
In numbers
- Trades disclosed
- 107
- Buys
- 0
- Sells
- 1
- Bought
- $0
- Sold
- $217K
- Companies
- 3
- Companies where not an officer
- 1
- First trade
- 1 Feb 2019
- Last trade
- 23 Feb 2026
- Last filed
- 25 Feb 2026
Companies traded
Activity over time
1 Feb – 1 Oct
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 23 Feb 2026filed 25 Feb 2026 | VERA Vera TherapeuticsBiotechnology | SEC FORM 4 Sold | $108K2,579 at $41.98 | filing |
| 23 Feb 2026filed 25 Feb 2026 | VERA Vera TherapeuticsBiotechnology | SEC FORM 4 Sold | $108K2,579 at $41.98 | filing |
| 20 Feb 2026filed 20 Feb 2026 | CRBU Caribou Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —45,000 at $0.00 | filing |
| 20 Feb 2026filed 20 Feb 2026 | CRBU Caribou Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —45,000 at $0.00 | filing |
| 4 Feb 2026filed 6 Feb 2026 | VERA Vera TherapeuticsBiotechnology | SEC FORM 4 Code A | —20,000 at $0.00 | filing |
| 4 Feb 2026filed 6 Feb 2026 | VERA Vera Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —40,000 at $0.00 | filing |
| 4 Feb 2026filed 6 Feb 2026 | VERA Vera Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —40,000 at $0.00 | filing |
| 4 Feb 2026filed 6 Feb 2026 | VERA Vera TherapeuticsBiotechnology | SEC FORM 4 Code A | —20,000 at $0.00 | filing |
| 20 Feb 2025filed 21 Feb 2025 | CRBU Caribou Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —40,500 at $0.00 | filing |
| 18 Feb 2025filed 20 Feb 2025 | VERA Vera Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —53,800 at $0.00 | filing |
| 18 Feb 2025filed 20 Feb 2025 | VERA Vera TherapeuticsBiotechnology | SEC FORM 4 Code A | —26,900 at $0.00 | filing |
| 1 Jul 2024filed 3 Jul 2024 | VERA Vera Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —160,000 at $0.00 | filing |
| 20 Feb 2024filed 22 Feb 2024 | CRBU Caribou Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —39,500 at $0.00 | filing |
| 21 Feb 2023filed 23 Feb 2023 | CRBU Caribou Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —21,500 at $0.00 | filing |
| 5 Oct 2022filed 6 Oct 2022 | Global Blood Therapeuticsoption or derivative | SEC FORM 4 Code D | —3,125 | filing |
| 5 Oct 2022filed 6 Oct 2022 | Global Blood Therapeuticsoption or derivative | SEC FORM 4 Code D | —10,935 | filing |
| 5 Oct 2022filed 6 Oct 2022 | Global Blood Therapeuticsoption or derivative | SEC FORM 4 Code D | —13,814 | filing |
| 5 Oct 2022filed 6 Oct 2022 | Global Blood Therapeuticsoption or derivative | SEC FORM 4 Code D | —15,460 | filing |
| 5 Oct 2022filed 6 Oct 2022 | Global Blood Therapeuticsoption or derivative | SEC FORM 4 Code D | —26,454 | filing |
| 5 Oct 2022filed 6 Oct 2022 | Global Blood Therapeuticsoption or derivative | SEC FORM 4 Code D | —42,400 | filing |
News
No headline names them, or the companies they trade most, lately.